PDS Biotechnology Corp (PDSB) Form 10-Q Quarterly Reports
PDS Biotechnology Corp (PDSB) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PDSB
CIK: 1472091
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 12/31/2018 12:00:00 AM
Lead Engagement PartnerMichael Guernsey
Audit LocationShort Hills, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| S-3 | 2026-10-14 | — | S-3 | 0001140361-26-039595 | View SEC Doc Filr Page |
| 8-K | 2026-10-06 | 2026-10-06 | 8-K | 0001140361-26-038728 | View SEC Doc Filr Page |
| 8-K | 2026-09-22 | 2026-09-22 | 8-K | 0001140361-26-037298 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2026-09-21 | — | SCHEDULE 13D Filing | 0001193125-26-397073 | View SEC Doc Filr Page |
| 3 | 2026-09-21 | 2026-09-14 | 3 | 0001193125-26-397028 | View SEC Doc Filr Page |
| 3 | 2026-09-21 | 2026-09-14 | 3 | 0001193125-26-397026 | View SEC Doc Filr Page |
| 8-K | 2026-09-21 | 2026-09-21 | 8-K | 0001140361-26-037234 | View SEC Doc Filr Page |
| 3 | 2026-09-18 | 2026-09-12 | FORM 3 | 0001140361-26-037142 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-12 | 8-K | 0001140361-26-036489 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-07 | 8-K | 0001140361-26-035853 | View SEC Doc Filr Page |
| 8-K | 2026-09-04 | 2026-08-31 | 8-K | 0001140361-26-035809 | View SEC Doc Filr Page |
| 8-K | 2026-08-25 | 2026-08-21 | 8-K | 0001140361-26-034320 | View SEC Doc Filr Page |
| 8-K | 2026-08-19 | 2026-08-13 | 8-K | 0001140361-26-033749 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-10 | 8-K | 0001140361-26-032947 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | 10-Q | 0001140361-26-032824 | View SEC Doc Filr Page |
| 8-K | 2026-08-13 | 2026-08-13 | 8-K | 0001140361-26-032650 | View SEC Doc Filr Page |
| 8-K | 2026-08-11 | 2026-08-11 | 8-K | 0001140361-26-032142 | View SEC Doc Filr Page |
| 8-K | 2026-07-31 | 2026-07-30 | 8-K | 0001140361-26-030497 | View SEC Doc Filr Page |
| EFFECT | 2026-07-21 | — | EFFECT Filing | 9999999995-26-002373 | View SEC Doc Filr Page |
| 424B4 | 2026-07-21 | — | 424B4 | 0001140361-26-029135 | View SEC Doc Filr Page |
| S-3 | 2026-07-10 | — | S-3 | 0001140361-26-028217 | View SEC Doc Filr Page |
| ARS | 2026-06-26 | 2025-12-31 | ARS | 0001140361-26-026577 | View SEC Doc Filr Page |
| DEFA14A | 2026-06-26 | — | DEFA14A | 0001140361-26-026570 | View SEC Doc Filr Page |
| DEF 14A | 2026-06-26 | 2026-08-10 | DEF 14A | 0001140361-26-026564 | View SEC Doc Filr Page |
| 424B5 | 2026-06-15 | — | 424B5 | 0001140361-26-025227 | View SEC Doc Filr Page |